Evidence is derived from placebo-controlled trials or observational real-world studies, which have produced heterogeneous results concerning comparative effectiveness, as while meta-analyses of the SMART-C consortium and other CVOTs position SGLT2 inhibitors as superior for preventing hospitalization for heart failure (HHF) and slowing CKD progression [3,7], the comparative efficacy of major adverse cardiovascular events (MACE), specifically stroke and myocardial infarction, remains debated. Here, SLC5A2 is linked to myocardial infarction.